| Title |
Impact of radiotherapy delay on survival in glioblastoma
|
|---|---|
| Published in |
Clinical and Translational Oncology, July 2012
|
| DOI | 10.1007/s12094-012-0916-x |
| Pubmed ID | |
| Authors |
Izaskun Valduvieco, Eugènia Verger, Jordi Bruna, Lluís Caral, Teresa Pujol, Teresa Ribalta, Teresa Boget, Laura Oleaga, Estela Pineda, Francesc Graus |
| Abstract |
Previous studies in glioblastoma have concluded that there is no decrease in survival with increasing time to initiation of RT up to 6 weeks after surgery. Unfortunately, the number of glioblastoma patients who start RT beyond 6 weeks is not small in some countries. The aim of our study was to evaluate the effect of RT delay beyond 6 weeks on survival of patients who have undergone completed resection of a glioblastoma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 53 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 13% |
| Student > Doctoral Student | 7 | 13% |
| Student > Bachelor | 7 | 13% |
| Student > Ph. D. Student | 5 | 9% |
| Unspecified | 4 | 7% |
| Other | 13 | 24% |
| Unknown | 12 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 53% |
| Unspecified | 4 | 7% |
| Neuroscience | 4 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 1 | 2% |
| Unknown | 13 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2013.
All research outputs
#15,267,294
of 22,703,044 outputs
Outputs from Clinical and Translational Oncology
#670
of 1,285 outputs
Outputs of similar age
#104,477
of 164,606 outputs
Outputs of similar age from Clinical and Translational Oncology
#21
of 43 outputs
Altmetric has tracked 22,703,044 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,285 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,606 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.